Anti-tumor necrosis factor (anti-TNF) is highly effective in inflammatory bowel disease (IBD); however, it is associated with an increased risk of infections, particularly in older adults. We reviewed 349 patients with IBD, who were observed over a 12-month period, 74 of whom had received anti-TNF therapy (71 patients were aged <60 years and 3 were aged ≥60 years). All the 3 older patients developed serious infectious complications after receiving anti-TNFs, although all of them were also on concomitant immunosuppressive therapy. One patient developed disseminated tuberculosis, another patient developed cholera diarrhea followed by nosocomial pneumonia, while the third patient developed multiple opportunistic infections (Pneumocystis pneumonia, cryptococcal septicemia and meningitis, Klebsiella septicemia). All 3 patients died within 1 year from the onset of the infection(s). We recommend that anti-TNF, especially when combined with other immunosuppressive therapy, should be used with extreme caution in older adult patients with IBD.

Citations

Citations to this article as recorded by  

• Infection toxicity assessment of tumor necrosis factor α inhibitors in the treatment of IBD: a real-world study based on the US food and drug administration adverse events reporting system (FAERS)
  Qian Cheng, Zeyu Yao, Xuan Shi, Shupeng Zou, Yazheng Zhao, Mengling Ouyang, Minghui Sun
  Expert Opinion on Drug Safety.2025; : 1.     CrossRef
• RATE OF INFECTION (TUBERCULOSIS) IN BRAZILIANS IBD PRIVATE PATIENTS: FOLLOW-UP 15 YEARS
  Didia B CURY, Liana C B CURY, Ana C MICHELETTI, Rogério A OLIVEIRA, José J S GONÇALVES
  Arquivos de Gastroenterologia.2024;[Epub]     CrossRef
• Cryptococcosis Associated With Biologic Therapy: A Narrative Review
  Xin Li, Olivier Paccoud, Koon-Ho Chan, Kwok-Yung Yuen, Romain Manchon, Fanny Lanternier, Monica A Slavin, Frank L van de Veerdonk, Tihana Bicanic, Olivier Lortholary
  Open Forum Infectious Diseases.2024;[Epub]     CrossRef
• Inflammatory bowel disease complicated with rare pathogen infection
  Jia-Heng Fang, Guo-Xiong Li
  World Chinese Journal of Digestology.2023; 31(1): 8.     CrossRef
• Pulmonary cryptococcosis after immunomodulator treatment in patients with Crohn’s disease: Three case reports
  Yan-Fei Fang, Xiang-Han Cao, Ling-Ya Yao, Qian Cao
  World Journal of Gastroenterology.2023; 29(4): 758.     CrossRef
• Systemic lupus erythematosus complicated by Crohn’s disease with rectovaginal fistula
  Heng Yeh, Ren-Chin Wu, Wen-Sy Tsai, Chia-Jung Kuo, Ming-Yao Su, Cheng-Tang Chiu, Puo-Hsien Le
  BMC Gastroenterology.2021;[Epub]     CrossRef
• Systematic review with meta‐analysis: biologics and risk of infection or cancer in elderly patients with inflammatory bowel disease
  Daniele Piovani, Silvio Danese, Laurent Peyrin‐Biroulet, Georgios K. Nikolopoulos, Stefanos Bonovas
  Alimentary Pharmacology & Therapeutics.2020; 51(9): 820.     CrossRef
• Safety of Biologic Therapy in Older Patients With Immune-Mediated Diseases: A Systematic Review and Meta-analysis
  Nienke Z. Borren, Ashwin N. Ananthakrishnan
  Clinical Gastroenterology and Hepatology.2019; 17(9): 1736.     CrossRef
• Improving Quality in the Care of Patients with Inflammatory Bowel Diseases
  Matthew D Egberg, Ajay S Gulati, Ziad F Gellad, Gil Y Melmed, Michael D Kappelman
  Inflammatory Bowel Diseases.2018; 24(8): 1660.     CrossRef